XNAS · Healthcare · Biotechnology
LB Pharmaceuticals Inc is a late-stage biopharmaceutical company developing novel therapies for the treatment of a wide range of neuropsychiatric disorders including schizophrenia, bipolar depression, adjunctive treatment of depressive disorder and other diseases. It is building a pipeline that leverages the broad therapeutic potential of its product candidate, LB-102, which it believes has the potential to be the first benzamide antipsychotic drug approved for neuropsychiatric disorders in the United States. LB-102 is currently in late-stage clinical development for schizophrenia and bipolar depression. The company operates as a single reportable segment in the development of novel therapies for the treatment of neuropsychiatric diseases, including schizophrenia.
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-05-12 | Q1 2026 | -0.69 | -0.67 | +2.90% | $0 | ✅ Beat | +0.10% | -12.40% | — |
| 2026-03-26 | Q4 2025 | -0.37 | -0.45 | -21.62% | $0 | ❌ Miss | +1.79% | +4.73% | +25.28% |
| 2025-11-06 |
| Q3 2025 |
| -0.57 |
| -0.61 |
| -7.02% |
| $0 |
| ❌ Miss |
| — |
| — |
| — |
Showing last 3 quarters.